Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the time to disease progression when everolimus and
pasireotide are given together in patients with advanced or metastatic HCC who have not had
any prior systemic therapy.